Clicky

MannKind Corporation(MNKD) News

Date Title
Jul 28 RBC Capital Lowered the PT on MannKind Corporation (MNKD), Kept a Buy Rating
Jul 23 MannKind Corporation (MNKD) Presented Inhaled Insulin Therapy At American Diabetes Association
Jul 17 Nontuberculous Mycobacteria (NTM) Opportunity Assessment and Forecast to 2033 Featuring Janssen, Novartis, Meiji Seika Pharma, Insmed, Daiichi Sankyo, MannKind, Paratek, Nobelpharma, GSK, Pfizer
Jul 14 High Growth Tech Stocks To Watch In The US July 2025
Jul 11 Wells Fargo Maintains a Buy Rating on MannKind Corporation (MNKD), Sets a $9 PT
Jun 25 Amarin (AMRN) Soars 27.3%: Is Further Upside Left in the Stock?
Jun 24 Leerink Partners Slashes MannKind Corporation’s (MNKD) Price Target to $7, Keeps a Buy Rating
Jun 9 MannKind to Highlight Data from Recent Pediatric and Adult Studies of Inhaled Insulin (Afrezza®) at American Diabetes Association’s 85th Scientific Sessions in Chicago, June 20-23
Mar 10 MannKind Showcases Efficacy, Safety, and Mealtime Control Data from Recent Pediatric and Adult Studies of Afrezza® at the ATTD Conference, March 19-22
Mar 1 MannKind Corporation Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Feb 28 MannKind Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags
Feb 27 MannKind Corp (MNKD) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ...
Feb 27 MannKind (MNKD) Q4 2024 Earnings Call Transcript
Feb 27 Compared to Estimates, MannKind (MNKD) Q4 Earnings: A Look at Key Metrics
Feb 26 MannKind (MNKD) Q4 Earnings Meet Estimates
Feb 26 MannKind: Q4 Earnings Snapshot
Feb 26 MannKind Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Feb 24 Exploring Three High Growth Tech Stocks in the United States
Feb 24 Unveiling MannKind (MNKD) Q4 Outlook: Wall Street Estimates for Key Metrics
Feb 19 MannKind Corporation to Hold 2024 Fourth Quarter and Full Year Financial Results Conference Call on February 26, 2025